Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next
Prelude Therapeutics – a small precision oncology biotech – suddenly became one of the market’s most volatile stocks in early November 2025. On Monday, Nov 3, PRLD shares skyrocketed, at one point gaining over 150%. The stock surged from roughly $1.60 into the $3–4 range, fueled by speculative buzz and unusually heavy tradingrttnews.com. More than 29 million shares changed hands in a single day, and the price hit a 52-week high of $4.19rttnews.com. By the session’s end, Prelude closed near $4 – an astronomical one-day move for a company of its size. However, the very next day, Tuesday Nov 4, the rally reversed sharply. Prelude announced major news before the market opened, and the stock was briefly halted for volatilityinvesting.com. After an initial pop of about 10% on the news, profit-taking set in; by late morning the stock had plunged ~40% from the prior day’s peaktipranks.com. It traded around $2.5 per share on Nov 4, still well above last week’s levels but far below Monday’s euphoric highs. This whiplash in price underscores the high-risk, high-reward nature of early-stage biotech stocks.
